Cortex Pharmaceuticals Inc.

The Irvine neuroscience company, which focuses on treatments for neurological and psychiatric disorders, said it lost $1.3 million, or 8 cents a share, for the first fiscal quarter, including $585,000 of noncash, stock-based compensation charges. Cortex lost $291,000, or 2 cents a share, for the corresponding period last year. Research, license and grant revenue for the quarter ended Sept. 30 declined 14% to $717,000.